News | February 14, 2012

Jury Awards $200,000 in Damages in IBA’S RadioMed Trial Against ONC Solutions

February 14, 2012 — A jury awarded RadioMed Corp. $200,000 from ONC Solutions as compensation for ONC using confidential and proprietary information in the development of its products starting in 2007. The case included patented information used in the development of the Visicoil, a gold tumor marker used to better guide radiation therapy.

RadioMed, a subsidiary of Ion Beam Applications (IBA), said it was prepared for any extension to this case should ONC Solutions appeal the verdict.

“We are very pleased the jury recognized the importance of protecting the intellectual property associated with Visicoil”, said Chuck Lindley, RadioMed chief operating officer. “RadioMed has invested significant time and resources in developing this patented cancer treatment technology.”

RadioMed became part of IBA in 2003. Visicoil is a patented (U.S. patent 8,027,712) helically wound gold coil available in various diameters and lengths to aid in the treatment of a range of radiation therapy techniques that target the prostate, lung, liver, pancreas, breast and other organs.

The clinical success of focused, dose-delivery procedures such as image guided radiation therapy (IGRT) and conformal radiation therapy (CRT) is based on the accuracy of target identification and precise patient positioning. Visicoil’s flexible coiled markers allow for accurate tumor localization, using a variety of visualization techniques. Visicoil is a general-purpose implanted fiducial marker. The marker is indicated for use to radiographically mark soft tissue for future therapeutic procedures, per U.S. Food and Drug Administration (FDA) cleared 510(K).

For more information: www.visicoil.com

Related Content

RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...
Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...